<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386398</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-21082</org_study_id>
    <secondary_id>EORTC-21082</secondary_id>
    <secondary_id>EU-21116</secondary_id>
    <secondary_id>EUDRACT-2009-011021-13</secondary_id>
    <nct_id>NCT01386398</nct_id>
  </id_info>
  <brief_title>Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth. It is not yet known whether vorinostat is more effective&#xD;
      when given alone or when given together with bortezomib in treating patients with refractory&#xD;
      or recurrent cutaneous T-cell lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well vorinostat works when given&#xD;
      alone compared with vorinostat given together with bortezomib in treating patients with&#xD;
      refractory or recurrent stage IIB, stage III, or stage IV cutaneous T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine if the combination of bortezomib plus vorinostat (SAHA) is more effective&#xD;
           than vorinostat alone, in terms of prolonging progression-free survival, in patients&#xD;
           with stage IIB-IV cutaneous T-cell lymphoma who have failed prior therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the overall survival of these patients.&#xD;
&#xD;
        -  To determine the response rate in these patients.&#xD;
&#xD;
        -  To determine the time to progression in these patients.&#xD;
&#xD;
        -  To determine the duration of response in these patients.&#xD;
&#xD;
        -  To determine the incidence of second cancers in these patients.&#xD;
&#xD;
        -  To determine the acute and late toxicity of this regimen in these patients.&#xD;
&#xD;
        -  To determine if translational research may provide insight into disease mechanism and&#xD;
           identify biomarkers useful for prediction of treatment response. (Exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to type of cutaneous&#xD;
      T-cell lymphoma (mycosis fungoides vs erythrodermic mycosis fungoides/Sézary syndrome),&#xD;
      number of prior chemotherapy regimens (1 vs ≥ 2), and country. Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral vorinostat (SAHA) once daily in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral vorinostat once&#xD;
           daily on days 1-14. Treatment repeats every 21 days until progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      Blood and tissue samples are collected periodically for translational research to provide&#xD;
      insight into disease mechanism and identify biomarkers useful for prediction of treatment&#xD;
      response.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks and then every 3&#xD;
      months until disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company withdrew interest&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second cancers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced cutaneous T-cell lymphoma (CTCL), including its&#xD;
             variants mycosis fungoides and Sézary syndrome&#xD;
&#xD;
               -  Stage IIB-IV disease&#xD;
&#xD;
          -  Relapsed or refractory disease, including any of the following:&#xD;
&#xD;
               -  Patients with clinical progression following EORTC-21081 protocol treatment&#xD;
&#xD;
               -  Intolerant to ≥ 1 prior intravenous chemotherapy, including denileukin diftitox,&#xD;
                  antibodies or antibody conjugates, or any other systemic therapy&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1.5 x 10^9/L*&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L*&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL*&#xD;
&#xD;
          -  WBC &gt; 3 x 10^9/L*&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN (in case of liver infiltration ≤ 5 x ULN)*&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL*&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Electrolytes (including potassium and magnesium) ≤ 1 times ULN*&#xD;
&#xD;
          -  Not pregnant or nursing prior to the first dose of study treatment and until 4 weeks&#xD;
             after the last study treatment&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  Able to swallow capsules and is able to take or tolerate oral medication on a&#xD;
             continuous basis&#xD;
&#xD;
          -  No New York Heart Association class III-IV disease&#xD;
&#xD;
          -  None of the following known conditions:&#xD;
&#xD;
               -  Infectious disease&#xD;
&#xD;
               -  Autoimmune disease&#xD;
&#xD;
               -  Immunodeficiency&#xD;
&#xD;
          -  No known or active HIV and/or hepatitis A, B, or C infection&#xD;
&#xD;
          -  No NCI CTC grade 1 peripheral sensory neuropathy with pain or peripheral sensory or&#xD;
             motor neuropathy ≥ grade II&#xD;
&#xD;
          -  No other malignancy within the past 5 years&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule NOTE: *Patients&#xD;
             with a buffer range from the normal values of +/- 5% for hematology and +/- 10% for&#xD;
             biochemistry are acceptable, except for renal function.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Must have completely recovered from previous treatment toxicity&#xD;
&#xD;
          -  No prior splenectomy or splenic irradiation&#xD;
&#xD;
          -  No prior bortezomib and/or histone deacetylase inhibitors (including vorinostat&#xD;
             [SAHA])&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy, immunotherapy, radiotherapy, or surgery&#xD;
&#xD;
               -  In case of clear progression during previous treatment, 2 weeks of wash-out is&#xD;
                  enough&#xD;
&#xD;
          -  No concurrent chemotherapy, immunotherapy, radiotherapy, or surgery (except biopsies)&#xD;
&#xD;
          -  No concurrent steroid (prednisone or equivalent) dose &gt; 20 mg/day&#xD;
&#xD;
               -  Prednisone ≤ 20 mg/day for treatment of disorders other than CTCL allowed&#xD;
&#xD;
          -  No concomitant use of other histone deacetylase inhibitors (e.g., valproic acid)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Luis Ortiz-Romero</last_name>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

